Researchers are now a step closer to finding treatment for dengue fever

July 31, 2014, SingHealth

There have been several news reports that the world's first dengue vaccine will be available next year. However, the latest clinical trials show that the vaccine only provides a protection of around 50 per cent for DENV-2 and DENV-1, which are commonly found in Singapore.

DENV-1 accounts for 90 per cent of infections locally as a large population lacks the immunity against this particular serotype. Until a vaccine that can offer higher protection becomes available, it is crucial to find a suitable treatment for , as there is presently none available world-wide.

The good news is that a team of Singapore General Hospital (SGH) and Duke-NUS Graduate Medical School (Duke-NUS) researchers are now a step closer to finding a treatment for fever. In the CELADEN study completed last year, the team found that Celgosivir, a medicine derived from a naturally occurring compound found in the seeds of the Moreton Bay Chestnut tree, is generally safe and well-tolerated by patients affected with the dengue virus.

Participants recruited for the study were admitted to SGH for five days, during which time they received either the placebo or Celgosivir. They continued to be followed up on days 7, 10 and 15 at the outpatient clinics where clinical histories and blood were taken. A physical examination of the patient was also done during these sessions.

"We found that the drug regimen in our CELADEN study was well-tolerated. And because dengue virus is cleared from the blood within three to five days and fever subsides in the same period, a regimen with more frequent dosing will be tested in the next phase of our trial to see its therapeutic effect," said Dr Jenny Low, Senior Consultant, Department of Infectious Diseases, SGH, and Principal Investigator of the study.

"Prior work conducted at Duke-NUS has demonstrated that dose regimen is an important factor in mediating the antiviral effects of Celgosivir," said Professor Subhash Vasudevan, Emerging Infectious Diseases Program at Duke-NUS.

The findings of the study were published in Lancet Infectious Diseases, a world-leading peer-reviewed scientific medical journal, on 28 May 2014.

Moving to the next phase of the study, SingHealth and Duke-NUS have signed an exclusive licensing agreement with 60 Degrees Pharmaceuticals to evaluate the efficacy and safety of an alternate dosing regimen as well as combination drug treatments in dengue patients. The NUS Industry Liaison Office, which is part of NUS Enterprise, took the lead in coordinating and facilitating this multi-party collaboration and the license negotiation.

"Other viral diseases such as hepatitis C and HIV required combination regimens to demonstrate clinical benefit. This may also be the case for dengue. To that end, 60P has also entered into a collaboration agreement with NUS earlier in March 2014 to investigate the utility of drug combinations in animal models. This agreement builds on prior collaborations between the parties to evaluate the antiviral effects of other approved drugs," said Mr Geoff Dow, CEO, 60P.

Dengue fever is an acute febrile illness transmitted by mosquitoes, which affects half the world's population. There are 96 million symptomatic infections, 500,0000 hospitalisations and 25,000 deaths per year attributed to the disease. The economic burden is $12 billion. In Singapore, as elsewhere, the incidence of the disease has continued to increase despite aggressive control measures.

Explore further: Researchers discover how dengue suppresses the human immune system

Related Stories

Researchers discover how dengue suppresses the human immune system

July 16, 2014
Scientists have discovered a new pathway the dengue virus takes to suppress the human immune system. This new knowledge deepens our understanding of the virus and could contribute to the development of more effective therapeutics.

World's most advanced dengue vaccine candidate shows promise in phase 3 trial

July 11, 2014
The first dengue vaccine candidate (CYD-TDV) to reach phase 3 clinical testing has shown moderate protection (56%) against the disease in Asian children, according to new research published in The Lancet.

Mast cells give clues in diagnosis, treatment of dengue

April 30, 2013
A protein produced by mast cells in the immune system may predict which people infected with dengue virus will develop life-threatening complications, according to researchers at Duke Medicine and Duke-National University ...

Tropical medicine study finds most rapid way to detect dengue

January 6, 2014
University of Hawaii Mānoa scientists have found that a commercially available, FDA-approved dengue detection kit bests the former "gold standard" test by producing results in under five hours.

Pitt CVR and Sanofi Pasteur collaborate to assess the effectiveness of a dengue vaccine

April 15, 2014
The University of Pittsburgh Center for Vaccine Research (CVR) and Sanofi Pasteur, the vaccines division of Sanofi, have entered a scientific collaboration to help assess the effectiveness of a dengue vaccine once introduced ...

Short sleep, aging brain

July 1, 2014
Researchers at Duke-NUS Graduate Medical School Singapore (Duke-NUS) have found evidence that the less older adults sleep, the faster their brains age. These findings, relevant in the context of Singapore's rapidly ageing ...

Recommended for you

Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

January 19, 2018
UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to ...

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Zika virus damages placenta, which may explain malformed babies

January 18, 2018
Though the Zika virus is widely known for a recent outbreak that caused children to be born with microencephaly, or having a small head, and other malformations, scientists have struggled to explain how the virus affects ...

Certain flu virus mutations may compensate for fitness costs of other mutations

January 18, 2018
Seasonal flu viruses continually undergo mutations that help them evade the human immune system, but some of these mutations can reduce a virus's potency. According to new research published in PLOS Pathogens, certain mutations ...

Study reveals how MRSA infection compromises lymphatic function

January 17, 2018
Infections of the skin or other soft tissues with the hard-to-treat MRSA (methicillin-resistant Staphylococcus aureus) bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.